Arcturus Therapeutics (NASDAQ:ARCT) Posts Earnings Results, Beats Estimates By $0.06 EPS

Arcturus Therapeutics (NASDAQ:ARCT) issued its earnings results on Thursday. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.01) by $0.06, FiscalAI reports. Arcturus Therapeutics had a negative net margin of 80.19% and a negative return on equity of 29.13%. The company had revenue of $2.06 million for the quarter, compared to analysts’ expectations of $6.30 million.

Here are the key takeaways from Arcturus Therapeutics’ conference call:

• Arcturus has begun enrollment in a 12-week open‑label Phase II of ARCT‑032 for Class 1 cystic fibrosis and reports patients have tolerated continuous inhaled dosing beyond one month, which the company attributes to its proprietary LUNAR delivery lipids and mRNA purification process.
• After a Type C meeting with the FDA, ARCT‑810 (OTC deficiency) received clear regulatory direction toward a pivotal pediatric development path; Arcturus is collecting additional exploratory data and plans an end‑of‑Phase II meeting in H2 2026.
• Financially, Arcturus reported $213.4 million in cash as of March 31, 2026 and says its cash runway extends beyond Q2 2028 following cost reductions and a strategic refocus on rare disease programs, despite a year‑over‑year revenue decline tied to reduced collaboration income.
• Partner Meiji is actively manufacturing Arcturus’ self‑amplifying mRNA COVID vaccine KOSTAIVE for Japan’s 2026/2027 season and will provide all commercial guidance, leaving Arcturus’ near‑term commercial exposure dependent on the partner.

Arcturus Therapeutics Trading Up 3.6%

Shares of NASDAQ:ARCT traded up $0.32 during trading on Friday, reaching $9.22. The stock had a trading volume of 931,609 shares, compared to its average volume of 470,122. Arcturus Therapeutics has a one year low of $5.85 and a one year high of $24.17. The company has a market capitalization of $262.03 million, a P/E ratio of -3.87 and a beta of 2.43. The firm’s 50-day simple moving average is $7.89 and its 200 day simple moving average is $7.83.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Piper Sandler dropped their target price on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Roth Mkm assumed coverage on shares of Arcturus Therapeutics in a report on Thursday, January 22nd. They set a “buy” rating and a $20.00 target price on the stock. B. Riley Financial assumed coverage on shares of Arcturus Therapeutics in a report on Wednesday, March 18th. They set a “buy” rating and a $22.00 target price on the stock. Citigroup dropped their target price on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Finally, Weiss Ratings upgraded shares of Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

Institutional Trading of Arcturus Therapeutics

A number of institutional investors have recently modified their holdings of the company. Osaic Holdings Inc. boosted its holdings in shares of Arcturus Therapeutics by 51.8% in the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 738 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Arcturus Therapeutics by 27.5% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 1,567 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Arcturus Therapeutics by 0.7% in the 2nd quarter. Bank of America Corp DE now owns 292,429 shares of the biotechnology company’s stock valued at $3,805,000 after buying an additional 2,098 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Arcturus Therapeutics by 163.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 2,586 shares in the last quarter. Finally, Two Sigma Investments LP boosted its holdings in shares of Arcturus Therapeutics by 3.3% in the 3rd quarter. Two Sigma Investments LP now owns 89,219 shares of the biotechnology company’s stock valued at $1,644,000 after buying an additional 2,857 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.